Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Sida 1 från 23 resultat
Fibrinogenolytic proteases with thrombolytic and antihypertensive activities: medical application and novel process of expression and production
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the purification and use of a novel family of fibrinogenolytic proteases. Specifically, this invention relates to a fibrinogenolytic protease which possesses a strong beta-fibrinogenolytic activity and does not cause
Protease-activated receptor 3 and uses thereof
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
This invention relates to nucleic acids, their encoded protease-activated receptor 3 proteins, and screening assays for agonists and antagonists of the protease activated receptor 3 proteins.
BACKGROUND OF THE INVENTION
Thrombin, a coagulation protease generated at sites of
DNA encoding a protease-activated receptor 3
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
This invention relates to nucleic acids, their encoded protease-activated receptor 3 proteins, and screening assays for agonists and antagonists of the protease activated receptor 3 proteins.
BACKGROUND OF THE INVENTION
Thrombin, a coagulation protease generated at sites of
Protease and related nucleic acid compounds
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
This application claims the benefit of U.S. Provisional Application No. 06/022,049, filed Jul. 22, 1996.
FIELD OF THE INVENTION
The present invention relates to an isolated ICE related protease and related DNA compounds encoding this protease. The invention further relates to the use of the ICE
Cysteinyl protease inhibitors
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
The invention relates to protease inhibitor compounds useful in treatments of neurodegenerative, cardiovascular, pulmonary, neuromuscular, musculovascular and autoimmune diseases characterized by tissue damage, induction of apoptosis, cell death and/or the accumulation of
Therapeutic application of Kazal-type serine protease inhibitors
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
This is a national stage entry of PCT/EP2008/001009, filed Feb. 11, 2008, which claims priority to EP 07002903.8, filed Feb. 12, 2007, all of which are incorporated herein by reference.
The subject of the present invention is, in the most general aspect, the therapeutic application of the Kazal-type
Interleukin-1 beta converting enzyme like apoptotic protease-6
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF INVENTION
This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists of
Interleukin-1.beta. converting enzyme like apoptotic protease-6
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF INVENTION
This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists of
Interleukin-1.beta. converting enzyme like apoptotic protease-6
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF INVENTION
This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists of
Interleukin-1 beta converting enzyme like apoptotic protease-7
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
Apoptosis, or programmed cell death (PCD), is a genetically regulated mechanism with a central role in both metazoan development and homeostasis. (Raff, 1992; Steller, 1995). The cell death machinery is conserved throughout evolution (Vaux et al., 1994) and is composed of
Interleukin-1 .beta. converting enzyme like apoptotic protease-6
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF INVENTION
This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists of
Methods and compositions for inhibiting apoptosis using serine protease inhibitors
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
1. FIELD OF THE INVENTION
The present invention relates to compositions and methods useful in the inhibition of apoptosis. Likewise, the present invention relates to methods of treating diseases associated with excessive or unregulated apoptosis.
2. BACKGROUND OF THE INVENTION
Normal development,
Modified MT-SP1 proteases that inhibit complement activation
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
INCORPORATION BY REFERENCE OF SEQUENCE LISTING PROVIDED ELECTRONICALLY
An electronic version of the Sequence Listing is filed herewith, the contents of which are incorporated by reference in their entirety. The electronic file was created on May 9, 2014, is 2,308 kilobytes in size, and titled
Sulfonamide derivatives
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a novel sulfonamide derivative. More particularly, it relates to a novel sulfonamide derivative or a salt thereof which shows a strong inhibitory activity against cysteine protease such as calpain, cathepsin B,
Arylsulfonamide ethers, and methods of use thereof
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
The invention relates to compounds that are inhibitors of interleukin-1.beta. converting enzyme. The invention also relates to pharmaceutical compositions comprising a compound of the present invention. The invention also relates to methods of treating stroke, inflammatory
Den mest kompletta databasen med medicinska örter som stöds av vetenskapen
- Fungerar på 55 språk
- Växtbaserade botemedel som stöds av vetenskap
- Örter igenkänning av bild
- Interaktiv GPS-karta - märka örter på plats (kommer snart)
- Läs vetenskapliga publikationer relaterade till din sökning
- Sök efter medicinska örter efter deras effekter
- Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent
Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning
